Why Freelancing Platform Upwork’s Shares Are Surging Today

Upwork Inc (NASDAQ: UPWK) shares are trading higher by around 20% after it reported 

Upwork Inc (NASDAQ:UPWK) shares are trading higher by around 20% after it reported Q3 FY23 results.

Revenue rose 11% Y/Y to $175.7 million, beating the consensus of $168.2 million.

Marketplace revenue increased 11% Y/Y to $161.7 million, led by take rate expansion on strength in the ads products and shift to a simplified, flat-fee pricing structure. 

Total take rate stood at 17.1% in Q3, vs. 15.4% a year ago, with Marketplace take rate of 15.9% (up from 14.3% the prior year).

The company signed 23 new Enterprise clients in Q3, up 21% Q/Q, and Gross Services Volume stood at $1 billion.

Active Clients rose 2% Y/Y to around 836,000 on improved client retention and the acquisition of new clients.

Adjusted EBITDA of $31.2 million was better than $(2.9) million a year ago, with EBITDA margin of 18% in Q3.

Adjusted EPS of $0.21 beat the consensus of $0.10. 

As of Q3-end, cash, cash equivalents, and marketable securities stood at around $555.2 million.

Also, the company’s Board has recently approved a $100 million share repurchase program.

FY23 Outlook: UPWK boosted guidance for revenue to $680 million-$685 million (from $665 million-$675 million) vs. consensus of $670.52 million, adjusted EBITDA to $67 million-$71 million (from $50.0 million-$55.0 million), and adjusted EPS to $0.47-$0.49 (from $0.36-$0.39) vs. $0.37 street view.

The company projects Q4 revenue of $175 million-$180 million (vs. consensus of $172.72 million), adjusted EBITDA of $24.0 million – $28.0 million, and adjusted EPS of $0.16-$0.18 vs. consensus of $0.16.

Price Action: UPWK shares are up by 19.92% at $14.42 premarket on the last check Wednesday.

Total
0
Shares
Related Posts
Read More

Reported Late Tuesday March 7, FDA Accepts Mesoblast’s Resubmission Of The Biologic License Application For Remestemcel-L In Children With Steroid-Refractory Acute Graft Versus Host Disease As A Complete Response And Sets Goal Date Of August 2, 2023

Mesoblast Limited (NASDAQ:MESO, ASX:MSB)))), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration's (FDA) Office of Therapeutic

MESO

Read More

Bulls Push Wall Street To Record Highs On Declining Inflation; Tech, Real Estate, Small Caps Surge Ahead Of Fed Meeting: What’s Driving Markets Wednesday?

A lower-than-expected inflation report for May ignited a bullish frenzy on Wall Street, with investors increasing their bets on rate cuts, bolstered by growing confidence that the Federal Reserve will ease its policy stance later this year as price pressures trend

$DOGE